Pembrolizumab,eftilagimod
novartis,Merck
['head and neck', 'immutep', '$immp']
$immp immutep reports final positive data in 2nd line head and neck squamous cell carcinoma at asco 2023 annual meeting #investing 
Stay ahead of the market with ultra-fast stock news updates. 
FREE with 15 sec delay. Upgrade to Gold for even faster news & exclusive features @ https://t.co/LViEqnfZ7i